Case Study—TAME Study with Dr Glenn Eastwood.
Spinnaker Case Study—We speak with Dr Glenn Eastwood, TAME Chief Principal Investigator, about the TAME Trial study and how Spiral has enabled them to produce a database they can be confident in.
Thousands more patients gain access to second ground-breaking antiviral via Panoramic
A new anti-viral, Paxlovid, has recently been added to the PANORAMIC national study in the UK.
REMAP-CAP: New Results for Antiplatelets in Critical COVID-19
The efficacy of antiplatelet therapy in critically ill patients with COVID-19 has always been uncertain. However recent findings have shown that it’s unlikely that adding an antiplatelet agent to anticoagulation will increase the number of organ support-free days in critically ill patients with COVID-19. Although it’s possible that survival in the first 90 days can be improved, according to the results of the REMAP-CAP trial.
Meet Mel - Spiral’s newest project manager
Meet Mel, the newest project manager to join our Spiral team. Mel has only been with us a few weeks but has settled into her role marvellously, bringing with her a background in project and account management as well as her recently acquired skills and knowledge in development.
The Panoramic Trial Reaches 20,000 Enrolments!
Over ten thousand participants from right across the UK have now taken part in the NIHR-funded and supported PANORAMIC trial - the world’s largest study into new antiviral treatments against COVID-19 in community, ambulatory care.
REMAP-CAP reaches new milestone
REMAP-CAP, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, has recently hit a significant date in its trial history, celebrating two years since the first Covid-19 ICU patient was randomised into the trial.
Saline just as effective as more expensive ‘balanced’ solutions - PLUS Study finds
The long-awaited results are finally here for the PLUS trial, an application in Spiral’s study manifest.
It’s official! The Panoramic trial is all go!
In a new development, we’re thrilled to report that the UK government has announced that thousands of the UK’s most vulnerable people will be among the first in the world to access these life-saving, cutting-edge antiviral and antibody treatments from December through the PANORAMIC trial.
Meet Adam, one of our Developers
Meet Adam. As the newest member to join our Spiral team, Adam has been with us for just over 6 months but has already brought with him a wealth of enthusiasm and keenness to take on a challenge.
Spiral joins first of its kind clinical trial - continuing the fight against COVID
Spiral is pleased to announce our involvement in another incredibly exciting trial, aimed at producing effective Covid-19 treatments for critical care patients.
Case Study - PLUS Study and The George Institute for Global Health
When it comes to clinical trials, we look to continue to make a difference around the world with our savvy software platform. We speak to Sharon Micallef, a trial project manager from The George Institute of Global Health, about her experience working with the team at Spiral to produce a database for her latest study.
Full-dose blood thinners benefit moderately ill COVID-19 patients
REMAP-CAP an application in Spiral’s study manifest, has recently been used in a collaborative clinical trial that focused on identifying effective treatments for critically ill Covid-19 patients.